[ad_1]
Packing containers of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Novo Nordisk on Monday stated it has lower the direct-to-consumer costs of its blockbuster weight reduction drug Wegovy and diabetes counterpart Ozempic, including to efforts by the corporate and the Trump administration to make the remedies extra accessible.
The Danish drugmaker is decreasing the value of the medication for current cash-paying sufferers to $349 per thirty days from $499 per thirty days. However Novo Nordisk stated the cash-pay price of the very best dose of Ozempic will stay $499 per thirty days.
Additionally on Monday, Novo Nordisk launched a short lived introductory supply, which can enable new cash-paying sufferers to entry the 2 lowest doses of Wegovy and Ozempic for $199 per thirty days for the primary two months of remedy. After that interval, individuals transfer to the brand new normal month-to-month direct-to-consumer value. The corporate’s introductory supply ends on March 31.
The bulletins come days after President Donald Trump struck offers with Novo Nordisk and chief rival Eli Lilly to make their in style GLP-1 medication simpler for People to entry and afford. These agreements will contain chopping the costs the federal government pays for the medication, introducing Medicare protection of weight problems medication for the primary time for sure sufferers and providing discounted medicines on the federal government’s new direct-to-consumer web site launching in January referred to as TrumpRx.
“Our new financial savings affords present speedy affect, bringing ahead higher price financial savings for individuals who are at present with out protection or select to self-pay,” stated Dave Moore, Novo Nordisk’s head of U.S. operations, stated in a launch. “It’s half of a bigger technique to increase entry that features constructing relationships with telehealth suppliers and main retailers, increasing protection, and dealing with the Administration to decrease prices for individuals residing with power illnesses like weight problems.”
The Trump administration stated beginning doses of current injections like Wegovy and Eli Lilly’s weight reduction drug Zepbound will probably be $350 per thirty days on TrumpRx, however will “development down” to $245 per thirty days over a two-year interval.
On the day the offers had been introduced, Eli Lilly stated it would decrease costs by $50 by itself direct-to-consumer platform, LillyDirect, which already affords Zepbound at a reduction to cash-paying sufferers. The multidose pen of Zepbound will probably be obtainable at $299 per thirty days on the lowest dose, with further doses being priced as much as $449 per thirty days.
Novo Nordisk’s new cash-pay affords can be found by way of Wegovy.com or Ozempic.com, the corporate’s direct-to-consumer pharmacy, NovoCare, and different taking part organizations and telehealth suppliers that work instantly with the drugmaker, together with Costco, GoodRx, WeightWatchers, Ro, LifeMD and eMed.
[ad_2]
